Evidence map›Paper›PMID 26308769›Full record

ArticleLeukemia2016

Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.

L Deng, Z Y Xu-Monette, S Loghavi, G C Manyam, Y Xia, C Visco, J Huh, L Zhang, Q Zhai, Y Wang and 22 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Trial
  2. Trial
  3. PD-L1Haematologica · 2018
    Trial
  4. Trial
  5. Observational
  6. Article
  7. Article
  8. Article
  9. A case of primary testicular adult T-cell leukemia/lymphoma (ATLL): ATLL of immune privileged site.Journal of clinical and experimental hematopathology : JCEH · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

L DengDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Z Y Xu-MonetteDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S LoghaviDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
G C ManyamDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Y XiaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
C ViscoSan Bortolo Hospital, Vicenza, Italy.
J HuhAsan Medical Center, Ulsan University College of Medicine, Seoul, Korea.
L ZhangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Q ZhaiTianjin Medical University Cancer Institute and Hospital, Institute of Hematology, CAMS & PUMC, Tianjin, China.
Y WangTianjin Medical University Cancer Institute and Hospital, Institute of Hematology, CAMS & PUMC, Tianjin, China.
L QiuTianjin Medical University Cancer Institute and Hospital, Institute of Hematology, CAMS & PUMC, Tianjin, China.
K DybkærAalborg University Hospital, Aalborg, Denmark.
A ChiuMemorial Sloan-Kettering Cancer Center, New York, NY, USA.
A M PerryUniversity of Manitoba, Winnipeg, MB, Canada.
S ZhangIndiana University School of Medicine, Indianapolis, IN, USA.
A TzankovUniversity Hospital, Basel, Switzerland.ORCID http://orcid.org/0000-0002-1100-3819
H RaoSun Yat-Sen University Cancer Center, Guangzhou, China.
J AbramsonMassachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
A R SohaniMassachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
M XuYale University School of Medicine, New Haven, CT, USA.
E D HsiCleveland Clinic, Cleveland, OH, USA.
J ZhuPeking University Cancer Hospital and Institute, Beijing, China.
M PonzoniSan Raffaele H Scientific Institute, Milan, Italy.
S WangNational University Hospital, Singapore, Singapore.
Ling LiThe First Affiliated Hospital of Zhengzhou University, Henan, China.
M ZhangThe First Affiliated Hospital of Zhengzhou University, Henan, China.
A J M FerreriSan Raffaele H Scientific Institute, Milan, Italy.
B M ParsonsGundersen Medical Foundation, La Crosse, WI, USA.
Y LiCleveland Clinic, Cleveland, OH, USA.
M A PirisHospital Universitario Marques de Valdecilla, Santander, Spain.
L J MedeirosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
K H YoungDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
P4 -TARGETING MULTIPLE MYELOMA BY COMBINING CDK INHIBITORS AND BCL-2 ANTAGONISTSP50CA142509 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2010 to 2014
$11.1M
PHARMACOGENOMICS OF CHILDHOOD LEUKEMIA (ALL)R37CA036401 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI EVANS, WILLIAM E · 1987 to 2014
$9.7M
Convergence of MicroRNAs and p53 Signaling in Multiple Myeloma: Environmental CoR01CA138688 · NCI · UNIVERSITY OF LOUISVILLE · PI LI, YONG · 2009 to 2017
$2.9M
UT M.D. Anderson Cancer Center Lymphoma SPOREP50CA136411 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2009 to 2011
$1.5M
Deep Sequencing of Small Regulatory RNAs in Diffuse Large B cell LymphomaRC1CA146299 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI XIAO, CHANGCHUN · 2009 to 2010
$1000k
NCI NIH HHS 1RC1CA146299NCI NIH HHS P30 CA016672NCI NIH HHS P50CA136411NCI NIH HHS P50CA142509NCI NIH HHS R01CA138688NCI NIH HHS R37 CA036401
6 · The paper itself

Abstract

Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is a unique subtype of DLBCL. The impact of rituximab on survival and patterns of treatment failure in PT-DLBCL patient remain controversial. We analyzed the clinical and biological feature of 280 PT-DLBCL cases, 64% of which were treated with rituximab-containing regimens. Although most (95%) patients achieved complete remission, a continuous risk of relapse was observed. Rituximab significantly reduced the cumulative risk of relapse (P=0.022) and improved both progression-free survival (PFS, P=0.012) and overall survival (OS, P=0.027) of PT-DLBCL patients (5-year PFS, 56% vs 36%; 5-year OS, 68% vs 48%). Central nervous system and contralateral testis were the most common sites of relapse, but other extranodal and nodal sites of relapse were also observed. Most cases of PT-DLBCL had a non-germinal center B-cell like (84%) immunophenotype and an activated B-cell like (86%) gene expression profile (GEP) subtype. The distinctive GEP signature of primary testicular lymphoma was relevant to tumor cell proliferation, dysregulated expression of adhesion molecules and immune response, likely accounting for the poor outcome. Accordingly, forkhead box P1 transcription factor (FOXP1) and T-cell leukemia/lymphoma 1 (TCL1) oncogenic activation were confirmed and predicted a significant trend of poor survival. This study provides valuable observations for better understanding of both clinical and biological features in PT-DLBCL patients.

Indexed as

AdolescentAdultAgedAged, 80 and overChildForkhead Transcription FactorsHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedProto-Oncogene ProteinsRecurrenceRepressor ProteinsRituximabTesticular NeoplasmsForkhead Transcription FactorsFOXP1 protein, humanProto-Oncogene ProteinsRepressor ProteinsRituximabTCL1A protein, human

Identifiers

PMID26308769

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.